Exscientia

British drug discovery company at Oxford, founded in 2012 out of research at the University of Dundee and listed on the American market in 2021, which used artificial intelligence to design small molecule medicines. Designed compounds that reached clinical trials in oncology and immunology, ran automated chemistry and patient tissue screening platforms, worked with Sanofi, Bristol Myers Squibb and other partners, and merged with Recursion in November 2024.